Portola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 Ameri...
November 28 2016 - 8:00AM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that clinical
and preclinical results from studies of all three of its
investigational drugs -- AndexXa™ (andexanet alfa), betrixaban and
cerdulatinib -- will be presented at the upcoming 58th American
Society of Hematology (ASH) Annual Meeting and Exposition, which is
taking place from December 3-6 at the San Diego Convention Center.
AndexXa, a U.S. Food and Drug Administration (FDA)-designated
Breakthrough Therapy, is in development for patients treated with a
direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin)
Factor Xa inhibitor when reversal of anticoagulation is needed due
to life-threatening or uncontrolled bleeding. Betrixaban, which has
Fast Track designation from the FDA, is an oral Factor Xa inhibitor
anticoagulant in development for the prevention of venous
thromboembolism (VTE) in acute medically ill patients.
Cerdulatinib, an oral, dual Syk/JAK kinase inhibitor, is in
development to treat patients with resistant or relapsed
hematologic cancer.
The abstracts are now available at
https://ash.confex.com/ash/2016/webprogram/start.html. Following
are details of the oral and poster presentations, which will
include additional data not available in the abstracts.
AndexXa™ (andexanet alfa)
- Abstract Title: Reversal of betrixaban-induced
anticoagulation in healthy volunteers by andexanet alfa
Publication
#:
143 Presenting
Author: Mark Crowther, M.D., MSc, FRCPC, Professor,
Department of Medicine, Hematology and Thromboembolism and
Pathology and Molecular Medicine, McMaster University, Hamilton,
Ontario Oral
Session Name: 332. Antithrombotic Therapy: Anticoagulation
and
Bleeding Presentation
Date and Time: Saturday, December 3, 1:00 p.m.
PT Presentation
Location: Room 30
- Abstract Title: Andexanet alfa reverses
anticoagulation effects of enoxaparin and associated bleeding in a
rabbit acute hemorrhage model
Publication
#:
1445 Presenting
Author: Pamela B. Conley, Ph.D., Vice President, Biology,
Portola
Pharmaceuticals Poster
Session Name: 332. Antithrombotic Therapy: Poster
I Presentation
Date and Time: Saturday, December 3, 5:30-7:30 p.m.
PT Location:
Hall GH
- Abstract Title: Andexanet alfa, a universal
antidote under development for Factor Xa inhibitors, reverses
rivaroxaban-induced inhibition of thrombin generation initiated by
the intrinsic coagulation pathway independent of TFPI
Publication
#:
3831 Presenting
Author: Genmin Lu, Ph.D., Senior Scientist, Portola
Pharmaceuticals Poster
Session Name: 332. Antithrombotic Therapy: Poster
III Presentation
Date and Time: Monday, December 5, 6:00-8:00 p.m.
PT Location:
Hall GH
Betrixaban
- Abstract Title: The safety and efficacy of
full versus reduced dose betrixaban in the Acute Medically Ill VTE
(venous thromboembolism) Prevention with Extended Duration
Betrixaban (APEX) trial
Publication
#:
3824 Presenting
Author: Russell Hull, MBBS, University of Calgary, R.A.H.
Faculty of Medicine, Alberta,
Canada Poster
Session Name: 332. Antithrombotic Therapy: Poster
III Presentation
Date and Time: Monday, December 5, 6:00-8:00 p.m.
PT Location:
Hall GH
Cerdulatinib
- Abstract Title: Regulation of B-cell receptor
signalling by the tumour microenvironment in chronic lymphocytic
leukemia (CLL) and its impact on adhesion and miRNA expression
Publication
#:
351 Presenting
Author: Andrew Steele, Ph.D., Associate Professor,
Medicine, University of Southampton, Southampton,
UK Oral
Session Name: 641. CLL: Biology and Pathophysiology,
excluding Therapy: CLL Microenvironment: Cell Intrinsic and
Extrinsic Factors
Presentation
Date and Time: Sunday, December 4, 10:00 a.m.
PT Location:
Room 5AB
- Abstract Title: Genetic or CD40L-mediated loss
of Iκbα is associated with resistance to the dual SYK/JAK inhibitor
cerdulatinib in DLBCL cell lines
Publication
#:
2768 Presenting
Author: Greg Coffey, Ph.D., Senior Scientist II, Portola
Pharmaceuticals Poster
Session Name: 605. Molecular Pharmacology, Drug Resistance
-- Lymphoid and Other Diseases: Poster II
Presentation
Date and Time: Sunday, December 4, 6:00-8:00 p.m.
PT Location:
Hall GH
About Portola Pharmaceuticals,
Inc. Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company is advancing three programs, including betrixaban, an
oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a Syk/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory conditions.
For more information, visit www.portola.com and follow the Company
on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
415.946.1087
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024